ATMPS's blockchain platform the world's first solution for personalized medicines?
New ‘blockchain ecosystem’ has potential to track, from vein-to-vein, advanced therapies.
ATMPS's Hataali blockchain platform has been successfully tested with University Hospitals Birmingham NHS Foundation Trust’s system interface.
Data interoperability was shown to be possible, rendering the Hataali platform as the world’s first blockchain solution for advanced therapeutic medicinal products (ATMP).
Hataali is a new pioneering blockchain-based cell orchestration platform that is interoperable with any other stakeholder interface and is designed to track advanced therapies from vein-to-vein.
University Hospitals Birmingham NHS Foundation Trust (UHB) hosts the Midlands and Wales Advanced Therapy Treatment Centre (MW-ATTC), which is a consortium of NHS, academic and industry partners.
The MW-ATTC — supported by Innovate UK — is one of three centres in the ATTC network across the UK working together to accelerate ATMP delivery in the NHS.
The informatics work, led by UHB within the MW-ATTC, proposes one NHS platform via which ATMP manufacturers could liaise with hospitals. The integration of cell orchestration platforms with UHB’s system will allow full and transparent visibility of samples and treatments.
“For the MW-ATTC project, we have been developing a prototype IT system that can record scheduling and ordering data for ATMP treatments. The system offers a number of integration points (APIs) to any cell orchestration platform such that the platform can communicate the relevant data to the prototype NHS IT system,” said Professor Philip Newsome, Director of MW-ATTC, University of Birmingham.
The MW-ATTC project, led by UHB, will form an effective example for the advanced therapy community tracking system to be rolled-out on a national scale.
“It’s a big moment for the ATMP space, as this is now the first network created anywhere in the world based on a blockchain technology. It’s been designed to provide the infrastructure for other stakeholders such as developers, third-party logistics and clinics to join on a secure, immutable and interoperable digital platform," commented, Raja Sharif, CEO of ATMPS Ltd.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.